Supapaan Teeraporn, Low Bee Y, Wongpoowarak Payom, Moolasarn Summana, Anderson Claire
Faculty of Pharmaceutical Sciences, Ubon Ratchathani University. Ubon Ratchathani (Thailand).
School of Pharmacy, Faculty of Science and Engineering, University of Nottingham Malaysia. Selangor, (Malaysia).
Pharm Pract (Granada). 2019 Jul-Sep;17(3):1611. doi: 10.18549/PharmPract.2019.3.1611. Epub 2019 Aug 21.
This review focuses on the studies and opinions around issues of transition from the BPharm to the PharmD degree in the U.S., Japan, South Korea, Pakistan and Thailand. The transition to the clinically orientated PharmD degree in many countries was seen to be a means of developing the profession. However, some countries have both clinically-oriented and pharmaceutical sciences-oriented PharmD programme that are designed to meet the needs of their countries. Each country created a different process to handle the transition to an all-PharmD programme, but mostly had the process of school accreditation mandated by the regulatory bodies. The main barrier to the transition in most of the countries was the issue of educational quality. A set of indicators is needed to measure and monitor the impact/outcome of the PharmD degree. Each country has different needs due to the different contexts of health care systems and the scope of pharmacy practice. In order to increase their chances of benefiting from the new programme, academic leaders should critically assess their countries' needs before deciding to adopt a PharmD programme.
本综述聚焦于美国、日本、韩国、巴基斯坦和泰国围绕从药学学士（BPharm）学位向药学博士（PharmD）学位过渡问题的研究和观点。在许多国家，向临床导向的药学博士学位过渡被视为该专业发展的一种方式。然而，一些国家既有临床导向型也有药学科学导向型的药学博士项目，旨在满足本国需求。每个国家都创建了不同的流程来处理向全药学博士项目的过渡，但大多都有监管机构强制要求的学校认证流程。大多数国家过渡的主要障碍是教育质量问题。需要一套指标来衡量和监测药学博士学位的影响/成果。由于医疗保健系统背景和药学实践范围不同，每个国家有不同的需求。为了增加从新计划中受益的机会，学术领袖在决定采用药学博士项目之前应审慎评估本国需求。
